Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

[Changes in lymphocyte surface expression of CD8 and CD38 molecules in peripheral blood of inactive HBsAg carriers following pegylated interferon a-2a therapy].

Yu HB, Ma LN, Liu YL, Hua W, He ZM, Lu JF, Chen XY.

Zhonghua Gan Zang Bing Za Zhi. 2013 Dec;21(12):895-8. doi: 10.3760/cma.j.issn.1007-3418.2013.12.004. Chinese.

PMID:
24636289
2.

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.

Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL.

Antivir Ther. 2012;17(1):9-17. doi: 10.3851/IMP1887.

PMID:
22267464
3.

The Predictive Value of Baseline HBsAg Level and Early Response for HBsAg Loss in Patients with HBeAg-positive Chronic Hepatitis B during Pegylated Interferon Alpha-2a Treatment.

Li MH, Zhang L, Qu XJ, Lu Y, Shen G, Li ZZ, Wu SL, Liu RY, Chang M, Hu LP, Hua WH, Song SJ, Wan G, Xie Y.

Biomed Environ Sci. 2017 Mar;30(3):177-184. doi: 10.3967/bes2017.025.

4.

[Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].

Zhu YY, Wu YL, Chen J, Zheng Q, Dong J, Jiang JJ.

Zhonghua Gan Zang Bing Za Zhi. 2012 Oct;20(10):737-41. doi: 10.3760/cma.j.issn.1007-3418.2012.10.006. Chinese.

PMID:
23207332
5.

A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha.

Cao Z, Liu Y, Ma L, Lu J, Jin Y, Ren S, He Z, Shen C, Chen X.

Hepatology. 2017 Oct;66(4):1058-1066. doi: 10.1002/hep.29213. Epub 2017 Aug 26.

PMID:
28407271
6.

Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment.

Li MH, Zhang L, Qu XJ, Lu Y, Shen G, Wu SL, Chang M, Liu RY, Hu LP, Li ZZ, Hua WH, Song SJ, Xie Y.

Chin Med J (Engl). 2017 Mar 5;130(5):559-565. doi: 10.4103/0366-6999.200554.

7.
8.

[Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].

Ji YJ, Li FF, Ren WH, Zhu YH, Qin CY.

Zhonghua Gan Zang Bing Za Zhi. 2013 May;21(5):335-9. doi: 10.3760/cma.j.issn.1007-3418.2013.05.006. Chinese.

PMID:
24025132
9.

[HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].

Chen XF, Chen XP, Ma XJ, Chen WL, Luo XD, Liao JY.

Zhonghua Gan Zang Bing Za Zhi. 2013 Jul;21(7):502-5. doi: 10.3760/cma.j.issn.1007-3418.2013.07.007. Chinese.

PMID:
24074707
10.

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.

Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Akarca US, Flisiak R, Verhey E, Van Vuuren AJ, Boucher CA, ter Borg MJ, Janssen HL.

Hepatology. 2010 Aug;52(2):454-61. doi: 10.1002/hep.23722.

PMID:
20683945
11.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

12.

Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.

Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P.

Hepatology. 2009 Apr;49(4):1151-7. doi: 10.1002/hep.22744.

PMID:
19115222
13.

Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.

Gheorghiţa VI, Caruntu FA, Curescu M, Olaru I, Radu MN, Colţan G, Streinu-Cercel A.

J Gastrointestin Liver Dis. 2013 Mar;22(1):27-32.

14.

[Efficacy and safety of peginterferon alfa-2a (40 kd) plus adefovir for 96 weeks in HBeAg-negative chronic hepatitis B patients].

Cao ZH, Ma LN, Liu YL, Jin Y, He ZM, Lu JF, Zhang YH, Chen XY.

Zhonghua Gan Zang Bing Za Zhi. 2013 Jul;21(7):498-501. doi: 10.3760/cma.j.issn.1007-3418.2013.07.006. Chinese.

PMID:
24074706
15.

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.

Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL.

Hepatology. 2010 Oct;52(4):1251-7. doi: 10.1002/hep.23844.

PMID:
20830787
16.

Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.

Cai Q, Chen F, Shao X, Zhang X, Zhao Z, Gao Z.

Antivir Ther. 2015;20(2):217-24. doi: 10.3851/IMP2832. Epub 2014 Aug 20.

PMID:
25138110
17.

Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.

Iannazzo S, Coco B, Brunetto MR, Rossetti F, Caputo A, Latour A, Espinos B, Bonino F.

Antivir Ther. 2013;18(4):623-33. doi: 10.3851/IMP2555. Epub 2013 Mar 13.

PMID:
23486701
18.

Pegylated interferon α enhances recovery of memory T cells in e antigen positive chronic hepatitis B patients.

Liu YZ, Hou FQ, Ding P, Ren YY, Li SH, Wang GQ.

Virol J. 2012 Nov 16;9:274. doi: 10.1186/1743-422X-9-274.

19.

HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels.

Jansen L, de Niet A, Stelma F, van Iperen EP, van Dort KA, Plat-Sinnige MJ, Takkenberg RB, Chin DJ, Zwinderman AH, Lopatin U, Kootstra NA, Reesink HW.

J Hepatol. 2014 Oct;61(4):730-7. doi: 10.1016/j.jhep.2014.05.004. Epub 2014 May 10.

PMID:
24824278
20.

Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.

de Niet A, Jansen L, Zaaijer HL, Klause U, Takkenberg B, Janssen HL, Chu T, Petric R, Reesink HW.

Antivir Ther. 2014;19(3):259-67. doi: 10.3851/IMP2707. Epub 2013 Nov 21.

PMID:
24256626

Supplemental Content

Support Center